TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01574027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: One capsule per day for six months
Study: NCT02886728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Capsule(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Capsule(s) administered orally once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Capsule(s) administered orally once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MTX
Description: Capsule(s) administered orally once weekly
Study: NCT01574027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule per day for six months
Study: NCT04132063

Intervention type: DRUG
Intervention: Generic levetiracetam
Description: Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
Study: NCT01804543

Intervention type: DRUG
Intervention: Ranolazine
Description: ranolazine 500 mg, then 1000 mg twice a day
Study: NCT03819569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small Renal Mass Biopsy
Description: Subjects will receive a small renal mass biopsy prior to making a treatment decision

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Small Renal Mass Biopsy
Description: Subjects will not receive a small renal mass biopsy prior to making a treatment decision
Study: NCT03230955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and psycho-educational support by phone
Description: The intervention is based on cognitive-behavioural therapy (CBT). The intervention, in order to achieve behavioural changes, will include components based in Bandura's social learning theory and social cognitive theory (Bandura, 1986) and the transtheorical model of change (Prochaska, 1992). It has been shown that expectations and self-efficacy are behavioural predictors and that they are an effective framework for the assistance to quit smoking. This theory allows evaluating patient motivation phase and adapting the interventions according to each phase (Fiore, 2011)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief counselling session
Description: Brief counselling session
Study: NCT00264043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: emboli capturing guidewire device combined with stent
Description: AngioGuard™ device and Bx Velocity™ stent
Study: NCT02687386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)
Description: EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
Study: NCT05439265

Intervention type: OTHER
Intervention: Electronic medical record order panel and resident involvement
Description: Prior to 2014, there was no formal process for evaluation of patients with HIT. In November of 2014, an EMR tool was created in an effort to improve heparin allergy documentation and HIT management. This EMR tool prompts the medical team to perform the 4T score, displays the appropriate HIT labs, alternative anticoagulation strategies, instructs the nurse to apply an allergy bracelet, and notifies the pharmacy resident through the order verification queue. The pharmacy resident then performs an independent 4T score, discontinues all heparin products, documents the heparin allergy in the medical record, and assesses the need for alternative anticoagulation.
Study: NCT01273649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy is given with other physical training
Study: NCT02116140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [C11]Acetate and HED PET
Study: NCT01822028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment A
Description: Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Study: NCT03082586

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 1
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 2
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 3
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 4
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 5
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 6
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
Study: NCT01822028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment B
Description: Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Study: NCT02395705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and paclitaxel
Description: 1. Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~2. Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~3. Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.
Study: NCT00684983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03712098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
Study: NCT00089583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir solution bid
Study: NCT00623077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) \> 1,000/mm\^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9.
Study: NCT03712098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
Study: NCT00623077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day divided in every 6 hrs dosing for 5 days.
Study: NCT03712098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
Study: NCT00623077

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole lung radiation
Description: At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
Study: NCT01609153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Coated tablet 5-20 mg milligram(s) per day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Coated tablet 5-20 mg milligram(s) per day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: 200-800 mg milligram(s)per day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: 200-800 mg milligram(s)per day for 16 weeks
Study: NCT02588781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
Study: NCT03504085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga: Active Hatha
Description: Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
Study: NCT01609153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine and Amisulpride
Description: Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine and Amisulpride
Description: Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks
Study: NCT04153513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanolin
Description: Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mother's milk
Description: After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
Study: NCT03016013

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus MTX
Description: The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160 mg plus MTX
Description: The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
Study: NCT03504085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga: Restorative
Description: Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
Study: NCT02779400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self testing INR device
Description: the procedure involves a series of repeated measurements of INR with the studied device
Study: NCT03815903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy
Description: 3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
Study: NCT04581824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
Study: NCT03815903

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
Study: NCT03867071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin injection
Description: Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: Intravenous injection 0,9% saline solution.
Study: NCT02704091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smecta
Study: NCT04581824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
Study: NCT02704091

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smecta placebo
Study: NCT02483195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Minoxidil
Description: This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg Spironolactone
Description: This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5mg Finasteride
Description: This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
Study: NCT04581824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.
Study: NCT04398706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 1
Description: Pharmaceutical form:liquid Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 1
Description: Pharmaceutical form:liquid Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 2
Description: Pharmaceutical form:liquid Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 2
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study: NCT03204786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Nasal Spray
Study: NCT03360786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific intervention
Description: Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Education on concussion and concussion identification in addition to typical cardiovascular warmups
Study: NCT00983788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: 3 x 200 mg/ day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03362307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Level Laser and Light-Emitting Diodes
Description: Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-Level Laser and Light-Emitting Diodes
Description: Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement
Description: A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dental implant placement
Description: A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
Study: NCT01469117

Intervention type: OTHER
Intervention: enteral formula
Description: Complete feeding of study enteral formula, route and regimen prescribed by the physician